NeuroOne Medical Technologies (NMTC) Competitors $0.81 -0.02 (-2.69%) Closing price 04:00 PM EasternExtended Trading$0.80 0.00 (-0.33%) As of 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock NMTC vs. LNSR, BSGM, RCEL, TLSI, LAKE, AVR, PDEX, MBOT, LUCD, and ICADShould you be buying NeuroOne Medical Technologies stock or one of its competitors? The main competitors of NeuroOne Medical Technologies include LENSAR (LNSR), Biosig Technologies (BSGM), Avita Medical (RCEL), TriSalus Life Sciences (TLSI), Lakeland Industries (LAKE), Anteris Technologies Global (AVR), Pro-Dex (PDEX), Microbot Medical (MBOT), Lucid Diagnostics (LUCD), and icad (ICAD). These companies are all part of the "medical equipment" industry. NeuroOne Medical Technologies vs. Its Competitors LENSAR Biosig Technologies Avita Medical TriSalus Life Sciences Lakeland Industries Anteris Technologies Global Pro-Dex Microbot Medical Lucid Diagnostics icad NeuroOne Medical Technologies (NASDAQ:NMTC) and LENSAR (NASDAQ:LNSR) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their analyst recommendations, profitability, risk, media sentiment, valuation, earnings, institutional ownership and dividends. Do insiders & institutionals have more ownership in NMTC or LNSR? 16.1% of NeuroOne Medical Technologies shares are owned by institutional investors. Comparatively, 40.2% of LENSAR shares are owned by institutional investors. 8.9% of NeuroOne Medical Technologies shares are owned by insiders. Comparatively, 66.0% of LENSAR shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term. Which has more volatility & risk, NMTC or LNSR? NeuroOne Medical Technologies has a beta of 0.68, suggesting that its share price is 32% less volatile than the S&P 500. Comparatively, LENSAR has a beta of 0.5, suggesting that its share price is 50% less volatile than the S&P 500. Do analysts prefer NMTC or LNSR? NeuroOne Medical Technologies currently has a consensus target price of $1.45, indicating a potential upside of 79.52%. LENSAR has a consensus target price of $15.00, indicating a potential upside of 20.00%. Given NeuroOne Medical Technologies' stronger consensus rating and higher possible upside, analysts plainly believe NeuroOne Medical Technologies is more favorable than LENSAR.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score NeuroOne Medical Technologies 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00LENSAR 0 Sell rating(s) 2 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00 Does the media refer more to NMTC or LNSR? In the previous week, NeuroOne Medical Technologies had 11 more articles in the media than LENSAR. MarketBeat recorded 13 mentions for NeuroOne Medical Technologies and 2 mentions for LENSAR. LENSAR's average media sentiment score of 0.88 beat NeuroOne Medical Technologies' score of 0.31 indicating that LENSAR is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment NeuroOne Medical Technologies 1 Very Positive mention(s) 1 Positive mention(s) 8 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Neutral LENSAR 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Is NMTC or LNSR more profitable? NeuroOne Medical Technologies has a net margin of -55.44% compared to LENSAR's net margin of -84.49%. NeuroOne Medical Technologies' return on equity of -163.49% beat LENSAR's return on equity.Company Net Margins Return on Equity Return on Assets NeuroOne Medical Technologies-55.44% -163.49% -78.67% LENSAR -84.49%-737.30%-72.60% Which has preferable valuation and earnings, NMTC or LNSR? NeuroOne Medical Technologies has higher earnings, but lower revenue than LENSAR. NeuroOne Medical Technologies is trading at a lower price-to-earnings ratio than LENSAR, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioNeuroOne Medical Technologies$3.45M11.71-$12.32M-$0.15-5.38LENSAR$53.49M2.79-$31.40M-$4.21-2.97 SummaryNeuroOne Medical Technologies beats LENSAR on 10 of the 16 factors compared between the two stocks. Get NeuroOne Medical Technologies News Delivered to You Automatically Sign up to receive the latest news and ratings for NMTC and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding NMTC and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart NMTC vs. The Competition Export to ExcelMetricNeuroOne Medical TechnologiesMedical Services IndustryMedical SectorNASDAQ ExchangeMarket Cap$41.50M$7.66B$5.73B$9.80BDividend YieldN/A2.76%4.54%4.08%P/E Ratio-5.3874.7930.7425.12Price / Sales11.7131.41441.05108.85Price / CashN/A23.8337.3459.16Price / Book5.0516.418.886.24Net Income-$12.32M$243.33M$3.26B$265.56M7 Day Performance1.48%1.53%1.73%0.90%1 Month Performance-4.98%2.00%3.54%1.88%1 Year Performance0.24%16.99%28.63%20.09% NeuroOne Medical Technologies Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)NMTCNeuroOne Medical Technologies2.8798 of 5 stars$0.81-2.7%$1.45+79.5%+13.7%$41.50M$3.45M-5.3820News CoverageEarnings ReportGap UpLNSRLENSAR1.0228 of 5 stars$12.92-0.8%$15.00+16.1%+191.8%$152.33M$53.49M-3.07110Negative NewsBSGMBiosig Technologies1.9627 of 5 stars$4.67+14.2%$10.00+114.1%+1,041.7%$146.31M$40K0.0050Earnings ReportRCELAvita Medical1.442 of 5 stars$5.52+14.8%$12.40+124.6%-38.9%$145.89M$64.25M-2.80130High Trading VolumeTLSITriSalus Life Sciences3.184 of 5 stars$3.65+2.2%$10.75+194.5%-15.5%$138.12M$29.43M-3.26106Earnings ReportAnalyst RevisionLAKELakeland Industries4.1442 of 5 stars$14.12+2.6%$26.00+84.1%-37.4%$134.28M$167.21M-4.692,100Positive NewsAVRAnteris Technologies GlobalN/A$3.71+6.0%$16.50+344.7%N/A$133.78M$2.70M0.00138PDEXPro-Dex2.67 of 5 stars$39.42+2.6%$56.00+42.1%+123.3%$128.51M$53.84M14.08140News CoveragePositive NewsAnalyst DowngradeHigh Trading VolumeMBOTMicrobot Medical1.5121 of 5 stars$3.12+8.0%$9.00+188.5%+202.0%$113.51MN/A-4.8020Earnings ReportLUCDLucid Diagnostics1.7786 of 5 stars$1.000.0%$3.55+255.9%+22.2%$107.92M$4.35M-0.7470Analyst UpgradeICADicadN/A$3.87flatN/AN/A$106.31M$19.61M-20.37140News Coverage Related Companies and Tools Related Companies LNSR Competitors BSGM Competitors RCEL Competitors TLSI Competitors LAKE Competitors AVR Competitors PDEX Competitors MBOT Competitors LUCD Competitors ICAD Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:NMTC) was last updated on 8/19/2025 by MarketBeat.com Staff From Our PartnersTrump’s national nightmare is herePorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | SponsoredThis is my Christian duty“This land I will give to you…” — a 4,000-year-old line from Genesis may hold the key to unlocking a $150 tril...Paradigm Press | SponsoredAlex’s “Next Magnificent Seven” stocksThe original “Magnificent Seven” turned $7K into $1.18 million. Now, Alex Green has identified AI’s Next Ma...The Oxford Club | SponsoredBONUS GUIDE - Ben Stein Prepares For the Next Financial CrisisWith inflation high, debt soaring, and global tensions rising, a financial storm may be brewing. Economist ...Goldco Precious Metals | SponsoredGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredOut of 18,347 Cryptocurrencies... This is the ONLY OneThe Single Most Undervalued DeFi Protocol You've Never Heard Of If there's one cryptocurrency you should b...Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding NeuroOne Medical Technologies Corporation Please log in to your account or sign up in order to add this asset to your watchlist. Share NeuroOne Medical Technologies With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access